Euler Biologics develops antibody-based therapeutics aimed at supporting physical function and independence in aging populations.
Euler Biologics has raised $493K in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2024.
Euler Biologics's investors include Gaingels.
Euler Biologics is headquartered in San Francisco, United States.
Euler Biologics develops antibody-based therapeutics aimed at supporting physical function and independence in aging populations.
Euler Biologics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Euler Biologics — Funding & Investors." VCBacked, October 15, 2024, https://www.vcbacked.co/company/euler-biologics. Accessed August 16, 2026.
VCBacked. (2024). Euler Biologics — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/euler-biologics
{{cite web |title=Euler Biologics — Funding & Investors |url=https://www.vcbacked.co/company/euler-biologics |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated